Brokerages Set TherapeuticsMD, Inc. (TXMD) PT at $14.86

Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) have earned an average recommendation of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.86.

A number of brokerages recently commented on TXMD. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. Morgan Stanley began coverage on shares of TherapeuticsMD in a research report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price objective for the company. Deutsche Bank set a $9.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th. Finally, Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th.

In related news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The stock was bought at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the transaction, the director now owns 3,555 shares in the company, valued at $22,076.55. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 23.92% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the company. Amalgamated Bank lifted its position in shares of TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after acquiring an additional 1,322 shares during the period. Principal Financial Group Inc. lifted its position in shares of TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after acquiring an additional 818 shares during the period. Virtu KCG Holdings LLC acquired a new stake in shares of TherapeuticsMD during the 2nd quarter valued at approximately $157,000. Quantbot Technologies LP acquired a new stake in shares of TherapeuticsMD during the 3rd quarter valued at approximately $189,000. Finally, Cetera Investment Advisers acquired a new stake in shares of TherapeuticsMD during the 2nd quarter valued at approximately $214,000. Institutional investors own 73.69% of the company’s stock.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded down $0.01 during trading hours on Tuesday, reaching $6.42. 1,635,300 shares of the company were exchanged, compared to its average volume of 2,810,000. The firm has a market capitalization of $1,390.00, a P/E ratio of -16.46 and a beta of 1.06. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm’s revenue was down 19.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.13) earnings per share. analysts anticipate that TherapeuticsMD will post -0.37 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set TherapeuticsMD, Inc. (TXMD) PT at $14.86” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3127768/brokerages-set-therapeuticsmd-inc-txmd-pt-at-14-86.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.